22-MULTI-48-AZ-PMC: D9950C00001 A Phase 1 First-in-human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination with Durvalumab (MEDI4736)

Grants and Contracts Details

StatusFinished
Effective start/end date7/13/22 → 6/28/23

Funding

  • AstraZeneca Pharmaceuticals LP (domestic): $15,000.00